A systemic evaluation of the effect of dsRNA contamination on mRNA vaccine expression and immunogenicity
The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Abstract
Double-stranded RNA (dsRNA) contamination generated during in vitro transcription (IVT) poses a significant challenge to the efficacy and safety of messenger RNA (mRNA) vaccines. This study systematically examined how varying dsRNA levels influence mRNA translation and immunogenicity using influenza hemagglutinin (HA) and human papillomavirus (HPV) E7 antigens as model systems, representing preventive and therapeutic vaccine targets, respectively. IVT-produced mRNA was synthesized using either uridine or N1-methyl-pseudouridine (m1Ψ) nucleosides, purified by cellulose chromatography, and supplemented with increasing synthetic dsRNA concentrations. In vivo experiments in mice revealed that high dsRNA concentrations markedly decreased antigen expression and increased pro-inflammatory cytokine production, regardless of nucleoside modification. Preventive HA mRNA vaccines containing elevated dsRNA levels showed decreased antibody titers and impaired T-cell responses. Conversely, therapeutic HPV E7 mRNA vaccines showed antigen-dependent variability; moderate dsRNA levels enhanced CD8+ T-cell responses, whereas higher concentrations were suppressive. Structural analysis of the RNA indicated that the HPV construct, with higher UTP content and reduced thermodynamic stability, generated more dsRNA during IVT, contributing to the observed immunostimulatory effects. Our findings indicate that dsRNA impurities act as a double-edged sword: low levels can function as beneficial immune adjuvants, whereas excessive amounts significantly hinder antigen expression and adaptive immunity. These results underscore the need for optimized dsRNA purification strategies tailored to specific antigens to balance immunogenicity and vaccine safety effectively. This study provides essential insights into refining mRNA vaccine production, highlighting the necessity of stringent control over dsRNA levels to maximize both preventive and therapeutic vaccine efficacy and minimize unintended inflammation.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
mRNA vaccines — a new era in vaccinology
Pardi, N., Hogan, M. J., Porter, F. W., & Weissman, D. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.243 · Cited by 4,667
Karikó, K., Muramatsu, H., Ludwig, J., & Weissman, D. (2011) · Nucleic Acids Research · doi:10.1093/nar/gkr695 · Cited by 898
mRNA-based therapeutics: powerful and versatile tools to combat diseases
Qin, S., Tang, X., Chen, Y., Chen, K., Fan, N., Xiao, W., Zheng, Q., Li, G., Teng, Y., Wu, M., et al. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01007-w · Cited by 771
A facile method for the removal of dsRNA contaminant from in vitro-transcribed mRNA
Baiersdörfer, M., Boros, G., Muramatsu, H., Mahiny, A., Vlatkovic, I., Sahin, U., & Karikó, K. (2019) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2019.02.018 · Cited by 569
Innate immune mechanisms of mRNA vaccines
Verbeke, R., Hogan, M. J., Loré, K., & Pardi, N. (2022) · Immunity · doi:10.1016/j.immuni.2022.10.014 · Cited by 501
Cellular origins of dsRNA, their recognition and consequences
Chen, Y. G., & Hur, S. (2022) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-021-00430-1 · Cited by 433
Double-Stranded RNA Sensors and Modulators in Innate Immunity
Hur, S. (2019) · Annual Review of Immunology · doi:10.1146/annurev-immunol-042718-041356 · Cited by 420
R-loops induce repressive chromatin marks over mammalian gene terminators
Skourti-Stathaki, K., Kamieniarz-Gdula, K., & Proudfoot, N. J. (2014) · Nature · doi:10.1038/nature13787 · Cited by 384
Tailoring mRNA Vaccine to Balance Innate/Adaptive Immune Response
Linares-Fernández, S., Lacroix, C., Exposito, J.-Y., & Verrier, B. (2020) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2019.10.002 · Cited by 376
Impact of mRNA chemistry and manufacturing process on innate immune activation
Nelson, J., Sorensen, E. W., Mintri, S., Rabideau, A. E., Zheng, W., Besin, G., Khatwani, N., Su, S. V., Miracco, E. J., Issa, W. J., et al. (2020) · Science Advances · doi:10.1126/sciadv.aaz6893 · Cited by 354
An origin of the immunogenicity of in vitro transcribed RNA
Mu, X., Greenwald, E., Ahmad, S., & Hur, S. (2018) · Nucleic Acids Research · doi:10.1093/nar/gky177 · Cited by 218
Intradermal delivery of modified mRNA encoding VEGF-A in patients with type 2 diabetes
Gan, L.-M., Lagerström-Fermér, M., Carlsson, L. G., Arfvidsson, C., Egnell, A.-C., Rudvik, A., Kjaer, M., Collén, A., Thompson, J. D., Joyal, J., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-08852-4 · Cited by 207
Triana-Alonso, F. J., Dabrowski, M., Wadzack, J., & Nierhaus, K. H. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.11.6298 · Cited by 207
Gholamalipour, Y., Karunanayake Mudiyanselage, A., & Martin, C. T. (2018) · Nucleic Acids Research · doi:10.1093/nar/gky796 · Cited by 180
Whitley, J., Zwolinski, C., Denis, C., Maughan, M., Hayles, L., Clarke, D., Snare, M., Liao, H., Chiou, S., Marmura, T., et al. (2022) · Translational Research · doi:10.1016/j.trsl.2021.11.009 · Cited by 176
dsRNA Released by Tissue Damage Activates TLR3 to Drive Skin Regeneration
Nelson, A. M., Reddy, S. K., Ratliff, T. S., Hossain, M. Z., Katseff, A. S., Zhu, A. S., Chang, E., Resnik, S. R., Page, C., Kim, D., et al. (2015) · Cell Stem Cell · doi:10.1016/j.stem.2015.07.008 · Cited by 174
RNase L Reprograms Translation by Widespread mRNA Turnover Escaped by Antiviral mRNAs
Burke, J. M., Moon, S. L., Lester, E., Matheny, T., & Parker, R. (2019) · Molecular Cell · doi:10.1016/j.molcel.2019.07.029 · Cited by 163
Immunogenicity of In Vitro-Transcribed RNA
Mu, X., & Hur, S. (2021) · Accounts of Chemical Research · doi:10.1021/acs.accounts.1c00521 · Cited by 134
Messenger RNA therapy for rare genetic metabolic diseases
Berraondo, P., Martini, P. G. V., Avila, M. A., & Fontanellas, A. (2019) · Gut · doi:10.1136/gutjnl-2019-318269 · Cited by 118
Personalized anti-cancer vaccine combining mRNA and immunotherapy tested in melanoma trial
Carvalho, T. (2023) · Nature Medicine · doi:10.1038/d41591-023-00072-0 · Cited by 104
Davis, S., & Watson, J. C. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.1.508 · Cited by 100
The Emerging Role of In Vitro-Transcribed mRNA in Adoptive T Cell Immunotherapy
Foster, J. B., Barrett, D. M., & Karikó, K. (2019) · Molecular Therapy · doi:10.1016/j.ymthe.2019.01.018 · Cited by 97
Camperi, J., Lippold, S., Ayalew, L., Roper, B., Shao, S., Freund, E. C., Nissenbaum, A., Galan, C., Cao, Q., Yang, F., et al. (2024) · Analytical Chemistry · doi:10.1021/acs.analchem.3c05539 · Cited by 80
Immunomodulatory Effects of dsRNA and Its Potential as Vaccine Adjuvant
Jin, B., Sun, T., Yu, X., Liu, C.-Q., Yang, Y.-X., Lu, P., Fu, S.-F., Hui-Bin, Q., & Yeo, A. E. T. (2010) · BioMed Research International · doi:10.1155/2010/690438 · Cited by 72
Exhaustion and over-activation of immune cells in COVID-19: Challenges and therapeutic opportunities
Alahdal, M., & Elkord, E. (2022) · Clinical Immunology · doi:10.1016/j.clim.2022.109177 · Cited by 65
Analyzing immune responses to varied mRNA and protein vaccine sequences
Park, H.-J., Bang, Y., Kwon, S. P., Kwak, W., Park, S., Roh, G., Bae, S., Kim, J., Kwak, H. W., Kim, Y., et al. (2023) · npj Vaccines · doi:10.1038/s41541-023-00684-0 · Cited by 57
Self-citationExogenous RNA surveillance by proton-sensing TRIM25
Kim, M., Pyo, Y., Hyun, S., Jeong, M., Choi, Y., & Kim, V. N. (2025) · Science · doi:10.1126/science.ads4539 · Cited by 55
Lee, S., Yoon, H., Hong, S. H., Kwon, S. P., Hong, J. J., Kwak, H. W., Park, H., Yoo, S., Bae, S., Park, H., et al. (2023) · Journal of Medical Virology · doi:10.1002/jmv.29309 · Cited by 47
Self-citationKano, Y., Iguchi, T., Matsui, H., Adachi, K., Sakoda, Y., Miyakawa, T., Doi, S., Hazama, S., Nagano, H., Ueyama, Y., et al. (2016) · Cancer Science · doi:10.1111/cas.12861 · Cited by 39
Myocarditis and COVID-19 Mrna Vaccines: A Mechanistic Hypothesis Involving dsRNA
Milano, G. A., Gal, J., Creisson, A., & Chamorey, E. (2021) · Future Virology · doi:10.2217/fvl-2021-0280 · Cited by 34
A novel defined TLR3 agonist as an effective vaccine adjuvant
Ko, K. H., Bin, S., Lee, S. H., Bae, H. S., Ham, C. S., Lee, M.-G., Kim, D.-H., & Han, S. H. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1075291 · Cited by 30
Self-citationZiegenhals, T., Frieling, R., Wolf, P., Göbel, K., Koch, S., Lohmann, M., Baiersdörfer, M., Fesser, S., Şahin, U., & Kuhn, A. N. (2023) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2023.1291045 · Cited by 30
Assessing the impact of mRNA vaccination in chronic inflammatory murine model
Lee, S., Lee, J., Cho, S., Roh, G., Park, H., Lee, Y.-J., Jeon, H.-E., Lee, Y., Bae, S., Youn, S. B., et al. (2024) · npj Vaccines · doi:10.1038/s41541-024-00825-z · Cited by 27
Self-citationPiao, X., Tang, Y., Li, X., Zhang, W., Yang, W., Xu, X., Wang, W., Jiang, J., Xu, J., Hu, K., et al. (2024) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2024.102223 · Cited by 19
Peña, A. C. D., Li, N., Vaduva, M., Bwanali, L., & Tripathi, A. (2023) · The Analyst · doi:10.1039/d3an00281k · Cited by 13
Qin, Q., Yan, H., Gao, W., Cao, R., Liu, G., Zhang, X., Wang, N., Zuo, W., Yuan, L., Gao, P., et al. (2024) · Journal of Molecular Biology · doi:10.1016/j.jmb.2024.168822 · Cited by 11
Cited by
Dissecting lipid nanoparticle adjuvanticity and reactogenicity to optimize vaccine formulations
Hirai, T., & Yoshioka, Y. (2026) · Current Opinion in Virology · doi:10.1016/j.coviro.2026.101540 · Cited by 4
A comprehensive analysis of the use of nucleoside analogues in RNA therapeutics
Kukushkina-Zvezdova, A. A., Zherebtsova, A. A., Telegina, D. V., Skvortsov, I. A., Ivanov, R. A., & Reshetnikov, V. V. (2026) · Journal of Translational Medicine · doi:10.1186/s12967-026-08083-4 · Cited by 3
“Conversely, gene replacement formulations demand a high degree of target protein biosynthesis and minimal reactogenicity to ensure safety and therapeutic longevity [345, 346].”
Krishna, V., Goyal, S. G., & Venuganti, V. V. K. (2026) · Medical Oncology · doi:10.1007/s12032-026-03349-9 · Cited by 1
dsRADAR: Imaging and Detecting Cellular dsRNA by Repurposing RNA‐Binding Proteins
Cheng, W., Todd, T. D., Quillin, A. L., Ingle, H., Halstead, A. M., Baldridge, M. T., Sáenz, J. B., & Heemstra, J. M. (2026) · Angewandte Chemie International Edition · doi:10.1002/anie.7655789 · Cited by 1
Engineering T7 RNA Polymerase for High-Purity In Vitro TranscriptionPreprint
Hermans, P., Serikova, Y., Castillo, J., Rooman, M. J., & Pucci, F. (2026) · arXiv (Cornell University) · doi:10.48550/arxiv.2607.18468 · Cited by 1
Metadata
- Authors
- Jo, S., Lee, J., Park, S.-I., Kim, Y., Yoon, S., Lee, S., Cho, S., Cho, Y., Oh, A., Ha, D., Choi, H., Kim, J., Lee, Y., Lee, S., Lee, S.-Y., Choi, E.-J., Roh, G., Lee, Y.-S., Bae, S.-H., Jeon, S., Park, H.-J., & Nam, J.-H.
- Affiliations
- Catholic University of Korea (KR)
- Daegu Haany University (KR)
- ORCID
- Venue
- Journal of Controlled Release
- Publisher
- Elsevier BV
- Published
- 2026-01
- Volume
- 389
- Pages
- 114471
- ISSN
- 0168-3659 (ISSN-L)
- OpenAlex
- W4416764636
- Cited by
- 14
- References
- 36
- Citations by year
- 2026: 14
- FWCI
- 2.72
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- doi.org/10.15223/policy-017 (stm-asf)
- doi.org/10.15223/policy-037 (stm-asf)
- doi.org/10.15223/policy-012 (stm-asf)
- doi.org/10.15223/policy-029 (stm-asf)
- doi.org/10.15223/policy-004 (stm-asf)
- Locations
- Journal of Controlled Release (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Korea Ministry of Health and Welfare (RS-2024-00507060)
- Korea Health Industry Development Institute
- Korea Ministry of Food and Drug Safety (22213MFDS421, RS-2025-02213409)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA and protein synthesis mechanisms
- Keywords
- mRNA vaccines, in vitro transcription, uridine nucleosides, influenza hemagglutinin, E7 oncoprotein, mRNA translation, immunogenicity, inflammatory cytokines, CD8+ T cell responses, vaccine adjuvants
- MeSH terms
- Immunogenicity, Vaccine, mRNA Vaccines, Animals, Drug Contamination, Female, Humans, Mice, Inbred C57BL, RNA, Double-Stranded, RNA, Messenger, CD8-Positive T-Lymphocytes, Hemagglutinin Glycoproteins, Influenza Virus, Papillomavirus E7 Proteins, Mice, Papillomavirus Vaccines
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.